Dr. Shmuel Cabilly
Dr. Cabilly is an investor and a board member of several companies. Dr. Cabilly developed a new technology for recombinant antibody production during a post-doctoral fellow at Genentech. This invention was patented in world patents “The old Cabilly” and “The New Cabilly patent”. Today there are already 20 drugs in the market based on this technology among which are Herceptin, Rituxan, Traceba, Raptiva, Xolair and more. Dr. Cabilly was also a co-founder and a chief scientist of Ethrog Biotechnology where he invented major technologies in the field of chemistry.